Despite millions of dollars of expenses, serum biomarkers such as S 100B and NSE remain research tools; perhaps because it is not particularly clear as to how proteins extravasating from neurons or glial cells end up in the systemic circulation. In fact, as a medical student I don't recall us ever reading about this topic or about the possibility of a brain lymphatic system. The systemic circulation, however, was a different story where lymphatic pathways are better defined.
In this report, Plog and colleagues examined the contribution of the glymphatic system in transport of TBI biomarkers to the peripheral blood. The work is based on recent observations of CSF movement through the recently characterized glymphatic pathway which transports biomarkers to blood via the cervical lymphatics without disrupting the blood brain barrier. The investigators manipulated the following: (1) AQP4 deletion, (2) cisterna magna cisternotomy, (3) acetazolamide treatment, and (4) sleep deprivation, based on their roles in altering glymphatic flow. The main findings are that clinically relevant manipulation of glymphatic activity, including sleep deprivation and cisternotomy, suppressed or eliminated TBI-induced increases in serum S100, GFAP, and neuron specific enolase. Interestingly, although the four mechanisms of glymphatic suppression result in differing degrees of inhibited radiotracer clearance, decreases in serum biomarker levels occurred to an equal extent, perhaps due to a floor effect of glymphatic suppression.
Although previous work has demonstrated that glymphatic CSF-ISF exchange drives the removal of exogenous molecules, including albumin, amyloid, dextrans, and paramagnetic contrast agents from the interstitial space of the brain, this work is exciting in particular because it shows for the first time, evidence of this pathway playing a critical role in the clearance of endogenously produced TBI protein biomarkers from the CNS to the peripheral blood. Future studies should consider the glymphatic pathway when examining the role of TBI biomarkers.
